亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Simultaneous Dual Type 2 Biologic Therapy Improves Sinonasal Outcomes in Selected Patients With Chronic Rhinosinusitis With Nasal Polyps

医学 鼻息肉 肉芽肿伴多发性血管炎 内科学 胃肠病学 哮喘 嗜酸性 慢性鼻-鼻窦炎 疾病 美波利祖马布 鼻窦炎 内型 联合疗法 年轻人 共病 嗜酸性粒细胞增多综合征 皮肤病科 生物制剂 病理生理学 嗜酸性粒细胞 显微镜下多血管炎 外科 疾病严重程度 鼻子 药物治疗 免疫病理学
作者
Friederike Bärhold,Jan Hagemann,Eugenio De Corso,Anna Sophie Hoffmann,Feifei Zhu,Patrick Huber,Moritz Gröger,Ulrike Förster‐Ruhrmann,Sietze Reitsma,Ludger Klimek
出处
期刊:Allergy [Wiley]
卷期号:81 (11): 3962-3971 被引量:1
标识
DOI:10.1111/all.70452
摘要

BACKGROUND: Due to the shared underlying pathophysiological mechanism, chronic rhinosinusitis with nasal polyps (CRSwNP) is frequently associated with comorbid systemic type 2 diseases. Rare, complex cases treated simultaneously with two biologics due to inadequate disease control have been reported. The aim of this study was to assess current use of dual biologic therapy in patients with CRSwNP. METHODS: This retrospective, multicentric study included adult patients with a diagnosis of severe uncontrolled CRSwNP and simultaneous dual type-2 biologic therapy, one of which had to be approved for the treatment of CRSwNP. Indication for dual therapy was made on an individual basis after interdisciplinary consultation. RESULTS: Thirty-four patients diagnosed with CRSwNP from six study centers in Germany, the Netherlands, and Italy were included (mean age 49.1, 55.9% female). Most patients showed complex medical histories with type 2 comorbidities and several futile treatment attempts. The combination therapy consisted of dupilumab/mepolizumab (n = 14), mepolizumab/tezepelumab (n = 2), or benralizumab/dupilumab (n = 14), dupilumab/omalizumab (n = 3), or dupilumab/tezepelumab (n = 1), with a median follow-up time of 25 months (IQR = 6-34). Most frequent comorbidities were asthma (n = 32), eosinophilic granulomatous polyangiitis (n = 13), and hypereosinophilic syndrome (n = 5). CRSwNP disease outcomes significantly improved under dual therapy at 6 months compared to baseline under single biologic therapy (SNOT22: -32.8, p < 0.0001; NPS: -3.2, p < 0.0001; Smell: +3.4, p = 0.003; VAS overall disease severity: -4.3, p = 0.054). Cessation of dual therapy was attempted in four patients, but reintroduced again due to loss of disease control. Five adverse reactions were reported in 4 (11.8%) patients: urticaria, erythema, gastrointestinal symptoms, weight gain, and arthralgia (each n = 1). CONCLUSIONS: In rare cases, dual biologic therapy can be indicated to control CRSwNP and comorbid type 2 diseases. The long-term efficacy and safety of this approach remain unknown and should be reserved for carefully selected cases only, considering the off-label use in some European countries and high associated costs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老实的石头完成签到,获得积分10
5秒前
霸气祥完成签到,获得积分10
5秒前
超帅的半莲完成签到,获得积分10
5秒前
16秒前
369ninja发布了新的文献求助10
22秒前
null的应助被纯情的阁采纳,获得10
32秒前
null的应助被纯情的阁采纳,获得10
32秒前
fairytaler的应助被纯情的阁采纳,获得10
32秒前
32秒前
范特西完成签到 ,获得积分10
43秒前
46秒前
缓慢的雨筠完成签到,获得积分10
50秒前
幽默的萍完成签到,获得积分10
1分钟前
1分钟前
爱笑美女完成签到,获得积分10
1分钟前
犹豫擎苍完成签到,获得积分10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
1分钟前
madeleinli的应助被纯情的阁采纳,获得10
2分钟前
慕青的应助被纯情的阁采纳,获得10
2分钟前
madeleinli的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
小蘑菇的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
2分钟前
2分钟前
单纯冰菱完成签到,获得积分10
2分钟前
2分钟前
火星上的山柳完成签到,获得积分10
2分钟前
2分钟前
大个的应助被Eva小飞鱼采纳,获得10
2分钟前
称心的忆山完成签到,获得积分10
2分钟前
2分钟前
agathahqs的应助被纯情的阁采纳,获得30
2分钟前
agathahqs的应助被纯情的阁采纳,获得10
2分钟前
agathahqs的应助被纯情的阁采纳,获得10
2分钟前
agathahqs的应助被纯情的阁采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158827
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2552000
邀请新用户注册赠送积分活动 2471370